MedTrace Logo

Letrozole vs. Clomiphene Citrate Plus Tamoxifen for Ovulation Induction and Pregnancy Outcomes.

NCT07616973 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-06-01

No results posted yet for this study

Summary

Infertility is a common reproductive health problem. Ovulation induction is a key treatment for women with anovulatory infertility. Letrozole and clomiphene citrate are widely used medications for ovulation induction. Tamoxifen has also been used as an alternative or adjunct therapy.

This randomized clinical trial aims to compare the effectiveness of letrozole versus clomiphene citrate combined with tamoxifen for ovulation induction and pregnancy outcomes in infertile women. The outcomes include ovulation rate, pregnancy rate, endometrial thickness, follicular development, Miscarriage rate, and Live birth rate.

The study will be conducted at Al-Thawra Hospital in Sana'a, Yemen, under the supervision of Sana'a University.

Keywords: Infertility, Ovulation Induction, Letrozole, Clomiphene Citrate, Tamoxifen

Conditions

  • Infertility Drugs
  • Infertility Involuntary

Interventions

DRUG

Letrozole

Letrozole was administered for ovulation induction in infertile women according to the study protocol.

DRUG

Clomiphene Citrate + Tamoxifen

Clomiphene citrate combined with tamoxifen was administered for ovulation induction in infertile women according to the study protocol.

Sponsors & Collaborators

  • Al-Thawra Modern General Hospital

    collaborator OTHER

  • Sana'a University

    lead OTHER

Principal Investigators

  • Ghada Abdullatef Al-Rajami, MD · Sana'a University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2026-05-30
Completion
2026-05-30

Countries

  • Yemen

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07616973 on ClinicalTrials.gov